Investigational drug · Phase 2
JYP0061
Also called: Experimental Drug Group
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Moderate-to-severe Atopic Dermatitis, Neuromyelitis Optica Spectrum Disorders.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "JYP0061"
First trial start
2023
May 24, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JYP0061", any sponsor or status.
Conditions studied
As listed on its trial records.
- Moderate-to-severe Atopic Dermatitis
- Neuromyelitis Optica Spectrum Disorders
Approved drugs for the same conditions: Atopic dermatitis (eczema) · Immunology and inflammation · Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "JYP0061" as an intervention, largest first.
- A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic DermatitisPivotal-lookingEnrolling by invitation
Guangzhou JOYO Pharma Co., LtdIndustry
NCT06158490 · 120 participants (planned) · Start Dec 27, 2023 · Primary completion Feb 10, 2026
Drug: JYP0061 15 mg; JYP0061 30 mg and 1 more · For: Moderate-to-severe Atopic Dermatitis
Sites: Shanghai, China
Guangzhou JOYO Pharma Co., LtdIndustry
NCT06137911 · 94 participants · Start Sep 26, 2021 · Primary completion Nov 9, 2022
Drug: JYP0061; placebo · For: Healthy Subjects
Sites: Shanghai, China
Guangzhou JOYO Pharma Co., LtdIndustry
NCT06697535 · 35 participants (planned) · Start May 24, 2023 · Primary completion Feb 28, 2026
Drug: JYP0061; Intravenous Glucocorticoids and 1 more · For: Neuromyelitis Optica Spectrum Disorders
Sites: Changsha, China
Newest research
PubMed records naming it or its code names, newest first.
- [A phase ࡲ clinical study to evaluate the efficacy and safety profile of antaitasvir phosphate combined with yiqibuvir in the treatment of adults with chronic hepatitis C].
Wei L, Shang J, An X, et al. · Zhonghua Gan Zang Bing Za Zhi 2025
- Pentoxifylline - A Novel Adjunct in the Management of Patients with Oral Submucous Fibrosis in Terai Population of Nepal: A Prospective Case Control Study.
Wazir SS, Srivastava R · Mymensingh Med J 2022
- Pentoxifylline therapy: a new adjunct in the treatment of oral submucous fibrosis.
Rajendran R, Rani V, Shaikh S · Indian J Dent Res 2006
- Fluoxetine dose and outcome in antidepressant drug trials.
Barbui C, Hotopf M, Garattini S · Eur J Clin Pharmacol 2002
- Effect of computer-generated prompts on physician prescribing of multiple daily doses.
Atkinson V, Andrews JD · Can J Hosp Pharm 1987
Also in development for Moderate-to-severe Atopic Dermatitis
- SHR-1819Phase 38 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Seasonal Allergic Rhinitis, Moderate to Severe Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- RezpegaldesleukinNKTR-358, REZPEGPhase 34 trials
Nektar Therapeutics · Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata
- AK139Phase 26 trials
Akeso · Asthma, Moderate-to-Severe Atopic Dermatitis, Chronic Spontaneous Urticaria
- QLS12010Phase 23 trials
Qilu Pharmaceutical Co., Ltd. · Adults With Moderate-to-severe Hidradenitis Suppurativa, Moderate-to-severe Atopic Dermatitis, Rheumatoid Arthritis (RA)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.